These in vivo results demonstrate that the TLR4/MyD88/NF-κB-dependent signaling pathway is aberrantly activated in keratinocytes by NETs, and that targeting of this pathway can lead to improvement in psoriasis-like inflammation. This evidence concerns the gene MYD88 and psoriasis.